Renerve Limited ( (AU:RNV) ) just unveiled an update.
ReNerve Limited reported a productive quarter with a 39% increase in sales, driven by the growing adoption of its NervAlign® Nerve Cuff, which has shown positive clinical results in improving patient outcomes for peripheral nerve repair. The company is expanding its US operations with the appointment of a new VP of Sales and Marketing and maintains a strong cash position of A$5.8 million to support its strategic initiatives. The NervAlign® Nerve Cuff has been well-received in various surgical applications, and ReNerve is on track to develop additional PNI products over the next four years.
More about Renerve Limited
ReNerve Limited is an Australian biotechnology company focused on developing innovative products for the repair of peripheral nerve injuries (PNI). The company’s primary product, the NervAlign® Nerve Cuff, is designed to assist in the surgical repair of damaged or transected nerves. ReNerve is expanding its market presence through partnerships outside the US and is also working on gaining FDA clearance for additional PNI products.
YTD Price Performance: -37.14%
Average Trading Volume: 248,874
See more data about RNV stock on TipRanks’ Stock Analysis page.